- Zacks•3 days ago
Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.
- PR Newswire•3 days ago
NORTH CHICAGO, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time. AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories.
- Investopedia•3 days ago
Venclexta, which was approved in the US, was rejected by the UK public health watchdog, NICE.
ABBV : Summary for AbbVie Inc. Common Stock - Yahoo Finance
AbbVie Inc. (ABBV)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||61.17 - 62.08|
|52 Week Range||53.74 - 68.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.02|
|Dividend & Yield||2.56 (4.14%)|
|1y Target Est||N/A|